Product Reports Resources Pricing Login Book a demo

Genocea Biosciences

Biotech & Life Sciences · Cambridge, United States · Founded 2006 · IPO 2014

Develops key breakthroughs in human vaccine discovery and development for antigens that induce T cell immunity MoreLess

Genocea Biosciences, based in Cambridge, is a pioneering bioscience company focused on developing personalized cancer vaccines and immunotherapies. The company operates in the biotechnology sector, specifically targeting cancer treatment through its innovative ATLAS platform. This platform identifies true T cell antigens, enabling the creation of tailored immunotherapies that are as unique as the individual cancers they target. Genocea's primary clients are cancer patients and healthcare providers seeking advanced treatment options. The company generates revenue through the development and commercialization of its proprietary cancer vaccines and immunotherapies. Genocea's business model involves extensive research and development, clinical trials, and partnerships with healthcare institutions to bring its therapies to market. The company's mission is to conquer cancer by leveraging the immune system's ability to recognize and fight cancer cells. Keywords: personalized cancer vaccines, neoantigen immunotherapies, T cell antigens, ATLAS platform, biotechnology, cancer treatment, healthcare providers, immunotherapy efficacy, clinical trials, bioscience.

Revenue $2.0M
Total funding $100–500M

Talent graph

Genocea Biosciences's talent

Book a demo to see the people
Team profiled 12 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

10 investors on Genocea Biosciences's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 7 investors entered at this stage
Polaris Partners
SR One
Morningside
Cycad Group
Lux Capital
Auriga Partners
Skyline Ventures
Series B+ 3 investors entered at this stage
Bill & Melinda Gates Foundation
Johnson & Johnson Development Corporation
MP Healthcare Venture Management

Global footprint

Where Genocea Biosciences has talent and traffic

Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

What the market is saying about Genocea Biosciences

An AI-synthesized read of the highest-engagement posts about Genocea Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Genocea Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.